Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Raw Materials (2016 - 2018)

Sanofi (SNY) has disclosed Raw Materials for 4 consecutive years, with $1.2 billion as the latest value for Q4 2018.

  • Quarterly Raw Materials rose 2.38% to $1.2 billion in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2018, up 2.38% year-over-year, with the annual reading at $1.2 billion for FY2018, 2.38% up from the prior year.
  • Raw Materials hit $1.2 billion in Q4 2018 for Sanofi, up from $1.1 billion in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.2 billion in Q4 2018 to a low of $1.0 billion in Q4 2016.
  • Historically, Raw Materials has averaged $1.1 billion across 4 years, with a median of $1.1 billion in 2015.
  • Biggest five-year swings in Raw Materials: fell 2.62% in 2016 and later rose 10.54% in 2017.
  • Year by year, Raw Materials stood at $1.1 billion in 2015, then dropped by 2.62% to $1.0 billion in 2016, then increased by 10.54% to $1.1 billion in 2017, then grew by 2.38% to $1.2 billion in 2018.
  • Business Quant data shows Raw Materials for SNY at $1.2 billion in Q4 2018, $1.1 billion in Q4 2017, and $1.0 billion in Q4 2016.